Cesare Patrone

Associate Professor/Senior Lecturer

Researh Group: https://ki.se/en/kisos/the-neurocardiometabol-group

In February 2009 I was recruited to Karolinska Institutet to start up a 
research group about the neurological complications of type 2 diabetes, with
main focus on stroke. I am responsible for planning, coordinating and
executing work in the area of experimental stroke in diabetes.

*2001-2009*: Senior Researcher and Manager at Neuronova AB, Stockholm, Sweden

*2000-2001: *Postdoctoral Fellow, Karolinska Institutet, Stockholm, Sweden

*1998-2000:* Postdoctoral Fellow, Uppsala University, Sweden

*1998: *PhD in Neurobiology, Milano University, Italy

Research grants and awards as PI 

1) The Swedish Research Council (Vetenskasprådet); 2022-2025

2) Hjärnfonden 2022

3) Hjärnfonden 2021

4) Diabetesfonden; 2020-2021

5) The Swedish Research Council (Vetenskasprådet); 2018-2021

6) European Foundation for the Study of Diabetes/Sanofi European DiabetesResearch Programme in Macrovascular Complications; 2019

 
7) Award “Investigator Study IIS” Boehringer Ing. Sweden; 2018

8) Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; 2012-2017

 
9) Åhlén Stiftelse; 2012-2018

10) O. E. och Edla Johanssons Stiftelse; 2016-2018

 
11) Magnus Bergvalls Stiftelse; 2011-2016

 
12) STROKE Riksförbundet; 2018-2020

 
13) Diabetesfonden; 2014-2015

14) Novo Nordisk Foundation; 2014

15) Syskonen Svensson Stiftelse; 2017

 
16) European Foundation for the Study of Diabetes; 2013

 
17) Diabetes Wellness; 2010

18) Stohnes stiftelse; 2010, 2012, 2015

 
19) STROKE Riksförbundet; 2011-2014

 
20) European Foundation for the Study of Diabetes; 2009

Courses

2018 Assess the structure of examination of projects, Workshop, Karolinska 
Institutet

2013 Docent in neuroscience, Karolinska Institutet

2011 Course in "Assessment in Higher Education", Karolinska Institutet

2011 Basic Course in Education for University Teachers, Karolinska 
Institutet

2010 Introductory Doctoral Supervision Course, Karolinska Institutet

2010 Work environment issues and manager responsibilities , Karolinska 
Institutet

2009 Laboratory Animal Science (FELASA) certificate, Karolinska Institutet

2008 Applied Project Management Courses, Wenell Management AB, Stockholm

2007 Courses in Clinical Trials, Trial Form Support AB, Lund

1998 PhD in Neurobiology, University of Milan, Italy.

1992 University of Milan, Italy, Laurea and M.Sc. Biological Sciences

Stroke and Diabetes
The focus is along two research lines, see also the Research Group at: https://ki.se/en/kisos/the-neurocardiometabol-group

1. The identification of efficacious preclinical therapies for the treatment of stroke in diabetes.
2. The study of the cellular mechanisms at the basis of the neurological complications of diabetes.

Stroke affects several million people worldwide, of which a substantial proportion of cases present in patients suffering from diabetes. Diabetes is
widespread and represents a leading cause of death. About 90 % of the medical and social costs associated with diabetes are dominated by care for macrovascular complications such as stroke. Therefore it is important to identify strategies aimed at prevent stroke in diabetes but also improve
post-stroke outcome in diabetic individuals.

1. We recently showed that decreasing weight in diabetes to the extent that glucose metabolism is normalized significantly improves stroke recovery: https://news.ki.se/weight-loss-may-repair-the-brain-after-stroke-in-diabetes [1] . The findings have been published in /Cardiovascular Diabetology/
2. GLP-1R agonists are commonly used drugs for the treatment of type 2 diabetes. We were the first in 2012 to show that the activation of the glucagon-like receptor 1 (GLP-1R) is neuroprotective against stroke in type 2 diabetic rodents. The findings have been published in /Clinical Science/:https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/22150224/ [2]
3. In 2021, we showed that this pharmacological strategy can also improve post-stroke functional recovery. The findings have been published in the British Journal of Pharmacology/https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/33973246/ [3]
4. We demonstrated a similar stroke efficacy as for the GLP-1R agonists for another class of clinically used drugs against diabetes called DPP-4 inhibitors. The findings were published in /Diabetes/ in 2012 https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/23209191/ [4] and 2021 https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/32540876/ [5]. See also the press release about the findings 2012 https://news.ki.se/diabetes-drug-may-reduce-brain-damage-after-stroke [6]
5. We identified several cellular mechanisms that are induced by diabetes and play a detrimental role in the impairment of stroke recovery. Among the most recent publications are the findings recently published in /Clinical Science /https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/31235555/ [7] and /Acta Neuropathologica Communications /https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/29471869/ [8]

[1] https://news.ki.se/weight-loss-may-repair-the-brain-after-stroke-in-diabetes
[2] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/22150224/
[3] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/33973246/
[4] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/23209191/
[5] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/32540876/
[6] https://news.ki.se/diabetes-drug-may-reduce-brain-damage-after-stroke
[7] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/31235555/
[8] https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/29471869/

July 2013- ongoing*, Project Coordinator/Examiner in degree projects in medicine, Department of Medical Epidemiology and Biostatistics [1], KI. The 
position involves reviewing the students’ work-plan, half time and final thesis, arrange seminars and examine the work.

 
2015- 2020* Visiting Professor (1 week/year), Univ. of Piemonte Orientale, Novara, Italy
[1] http://ki.se/ki/jsp/polopoly.jsp?d=9600&;amp;l=en